Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL ((R-HAD))

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01449344
Recruitment Status : Unknown
Verified March 2017 by Prof. Dr. M. Dreyling (co-chairman), European Mantle Cell Lymphoma Network.
Recruitment status was:  Active, not recruiting
First Posted : October 10, 2011
Last Update Posted : March 7, 2017
Sponsor:
Collaborators:
Klinikum der Universitaet Muenchen, Grosshadern
ClinAssess GmbH
GELARC Service de Pharmacovigilance, Pierre Benite
Information provided by (Responsible Party):
Prof. Dr. M. Dreyling (co-chairman), European Mantle Cell Lymphoma Network

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018